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ABSTRACT Bipolar mood disorder (BP) is a debilitating
syndrome characterized by episodes of mania and depression.
We designed a multistage study to detect all major loci
predisposing to severe BP (termed BP-I) in two pedigrees
drawn from the Central Valley of Costa Rica, where the
population is largely descended from a few founders in the
16th–18th centuries. We considered only individuals with BP-I
as affected and screened the genome for linkage with 473
microsatellite markers. We used a model for linkage analysis
that incorporated a high phenocopy rate and a conservative
estimate of penetrance. Our goal in this study was not to
establish definitive linkage but rather to detect all regions
possibly harboring major genes for BP-I in these pedigrees. To
facilitate this aim, we evaluated the degree to which markers
that were informative in our data set provided coverage of
each genome region; we estimate that at least 94% of the
genome has been covered, at a predesignated threshold de-
termined through prior linkage simulation analyses. We re-
port here the results of our genome screen for BP-I loci and
indicate several regions that merit further study, including
segments in 18q, 18p, and 11p, in which suggestive lod scores
were observed for two or more contiguous markers. Isolated
lod scores that exceeded our thresholds in one or both families
also occurred on chromosomes 1, 2, 3, 4, 5, 7, 13, 15, 16, and
17. Interesting regions highlighted in this genome screen will
be followed up using linkage disequilibrium (LD) methods.
Bipolar mood disorder (BP) is a debilitating syndrome char-
acterized by episodes of mania and depression (1). Despite
abundant evidence that BP has a major genetic component
(2–5), linkage studies have not yet succeeded in definitively
localizing a BP gene (6). This is chiefly because mapping
studies of psychiatric disorders have generally been conducted
under a paradigm that was appropriate for mapping genes for
simple Mendelian disorders, namely, using linkage analysis in
the expectation of finding high lod (logarithm of odds) scores
that definitively signpost the location of disease genes. The
follow-up to early BP linkage studies, however, showed that
even extremely high lod scores at a single location can be false
positives (7–10). The instability of the findings in these studies
was at least partially due to the genetic models chosen for
initial analyses, which incorporated broadly defined affected
phenotypes, low phenocopy rates, and high penetrances; this
approach set the stage for a precipitous diminution in the
evidence for linkage when diagnoses for a few members of the
original pedigrees changed over time (2, 5, 9, 10). In fact, the
difficulty in defining behavioral phenotypes, their probable
etiologic heterogeneity, and our lack of knowledge regarding
their mode of transmission suggest that it is unlikely that any
single linkage study will yield sufficient evidence to unequiv-
ocally localize a gene for a psychiatric disorder. Given this
uncertainty, we propose that initial linkage studies be con-
ducted using a conservative approach (affected phenotypes are
narrowly defined and most linkage information derives from
affected individuals) and that the results of lod score analysis
be used for directing follow-up studies rather than as formal
linkage tests. Despite the uncertainty in estimating genetic
model parameters for complex traits, lod score analysis using
large pedigrees is still an efficient means of initially screening
the genome to detect hints of linkage over broad regions; as
affected individuals in such pedigrees are separated from each
other by only a few generations, few recombinations between
a linked marker and a disease gene are likely to be observed
over intervals of 10–15 centimorgans (cM) (the typical dis-
tances between markers used in our study) (11).
Fortunately, the recent availability of highly polymorphic,
genetically mapped markers covering the genome (12–14) has
enabled the development of a multistage paradigm for map-
ping genes for complex traits. In the first stages, complete
genome screening (e.g., through lod score analysis) is used to
identify possible localizations for disease genes. Subsequently,
the regions highlighted by the screening study are more
intensively investigated to confirm the initial localizations and
delineate clear candidate regions. Finally, fine mapping meth-
ods [such as haplotype or linkage disequilibrium (LD) analysis]
or candidate gene approaches are used for positional cloning
of disease genes. Such multistage strategies have recently been
used to map (15–21) and clone (22) genes for complex
nonpsychiatric disorders despite the absence of standard link-
age data meeting traditional criteria for significance.
Our genome screening study for BP employed the strategies
used to map genes for complex nonpsychiatric diseases (6).
Unlike previous genetic studies of BP, this study considered as
affected only those individuals with the most severe and
clinically distinctive forms of BP (BP-I and schizoaffective
disorder, manic type, SAD-M), rather than including those
diagnosed with a milder form of BP (BP-II) or with unipolar
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major depressive disorder (MDD). We studied two large
pedigrees (CR001 and CR004) from a genetically homoge-
neous population, that of the Central Valley of Costa Rica (23,
24). We screened the entire genome for linkage by using
mapped microsatellite markers and a model for genetic anal-
ysis in which most of the linkage information derived from
affected individuals. The goal of our stringent linkage analysis
was to identify all regions potentially harboringmajor genes for
BP-I in the study population, rather than to establish definitive
linkage. We derived predesignated lod score thresholds (using
linkage simulation analyses), to suggest regions worthy of
further investigation. Importantly, although we anticipate ob-
serving LD in the immediate vicinity of a disease gene among
affected individuals in a population (such as that of the Central
Valley) with a small number of founders, this expectation does
not invalidate the assumption usually made for standard lod
score analysis that markers are in linkage equilibrium with
each other—i.e., their alleles are not associated. This is
because the 10- to 20-cM chromosomal regions over which one
is searching for evidence of linkage with the lod score method
(i.e., cosegregation of marker and trait loci) are larger than
those over which one expects to observe LD (i.e., allelic
association) even in such a population (11, 19).
We performed the genome screening in two stages. The
goals of the stage I screen were to identify areas suggestive of
linkage, so that we could saturate them with available markers,
and to pinpoint regions, referred to as ‘‘coverage gaps,’’ where
markers were insufficiently informative in our sample to detect
evidence of linkage. The goal of the stage II screen was to
follow up on regions flanking each marker that yielded peak
lod scores approximately equal to or greater than the thresh-
olds used for the coverage calculations, which were deemed
regions of interest, and to fill in coverage gaps. We report here
the results of our complete genome screening (stages I and II)
using 473 markers.
MATERIALS AND METHODS
Pedigrees.We studied two independently ascertained Costa
Rican pedigrees (CR001 and CR004) that were chosen be-
cause they contained a high density of individuals with BP-I
and because their ancestry could be traced to the founding
population of the Central Valley of Costa Rica (24). The
current population of the Central Valley (consisting of about
two million people) is predominantly descended from a small
number of Spanish and Amerindian founders in the 16th and
17th centuries (23). Studies of several inherited diseases have
confirmed the genetic isolation of this population (25, 26). An
extensive description of pedigrees CR001 and CR004 is pro-
vided in a separate paper (24). In the course of the study we
discovered two links between these pedigrees (one occurred
several generations ago and one occurred in a recent gener-
ation). We analyzed the families separately, however, because
these links were discovered after the simulation analyses were
completed and after the genome screening study had been
initiated.
All available adult members of these families were inter-
viewed in Spanish, using the Schedule for Affective Disorders
and Schizophrenia Lifetime version (SADS-L) (27). Individ-
uals who received a psychiatric diagnosis were interviewed
again in Spanish by a research psychiatrist using the Diagnostic
Interview for Genetic Studies (DIGS) (28). The interviews and
medical records were then reviewed by two blinded best
estimators who reached a consensus diagnosis. The diagnostic
procedures are described in detail in ref. 24.
Genotyping Studies. We used linkage simulations to select
the most informative individuals from pedigrees CR001 and
CR004 for genotyping studies (24). Under a 90% dominant
model, simulation analyses with these individuals suggested
that we would likely detect evidence of linkage (e.g., a prob-
ability of 92% of obtaining lod. 1.0 in the combined data set),
using markers with an average heterozygosity of 0.75 spaced at
10-cM intervals (as discussed in ref. 24). For the stage I screen,
we chose the most polymorphic markers (307 in total) placed
at approximately 10-cM intervals on the 1992 Genethon map
(11). These markers were then supplemented by a small
number of markers from the Cooperative Human Linkage
Center (CHLC) public data base. For the stage II screen we
added 166 markers from newer Genethon and CHLC maps as
they became available (13, 14) and from the public data base
of the Utah Center for Genome Research. Genotyping pro-
cedures were as described previously (29). Briefly, one of the
two PCR primers was labeled radioactively by using a polynu-
cleotide kinase, and PCR products were separated by electro-
phoresis on polyacrylamide gels. Autoradiographs were scored
independently by two raters. Data for each marker were
entered into the computer data base twice, and the resultant
files were compared for discrepancies.
Statistical Analyses. Two-point linkage analyses were per-
formed for all markers. Marker allele frequencies were esti-
mated from the combined data set with correction for depen-
dency due to family relationships (30). The linkage analyses
included the 65 individuals who were genotyped as well as an
additional 65 individuals who had been diagnostically evalu-
ated but not genotyped. Only individuals with BP-I were
considered affected, with the exception of two persons, one in
each family, who carry diagnoses of SAD-M. The SAD-M
individuals were included as affected because BP-I and
SAD-M co-segregate in families and they are often difficult to
distinguish from each other on the basis of their clinical
presentation and course of illness (1, 2, 24). In all, we
designated as affected 20 individuals within CR004 (16 avail-
able for genotyping) and 10 individuals from CR001 (8 avail-
able for genotyping). The phenotype for all other individuals
was considered unknown except for 17 individuals who were
designated as unaffected if they carried no psychiatric diag-
noses and were well beyond the age of risk for BP-I (these
individuals contributed little information to the linkage anal-
ysis).
Linkage analyses were performed using a nearly dominant
model (assuming penetrance of 0.81 for heterozygous individ-
uals and 0.9 for homozygotes with the disease mutation). This
model was chosen from five different single-locus models
(ranging from recessive to nearly dominant) because it seemed
most consistent with the segregation patterns of BP in the two
pedigrees and because it had demonstrated the greatest power
to detect linkage in simulation studies (24). On the basis of
Costa Rican epidemiological surveys (23), we assumed the
population prevalence of BP-I to be 0.015 (and thus the
frequency of the disease allele to be 0.003). The frequency of
BP-I in individuals without the disease allele was set at 0.01,
which effectively specified a population phenocopy rate of 0.67
(i.e., an affected individual in the general population has a 2y3
probability of being a phenocopy). For multiply affected
families, the probability that a gene is segregating is highly
increased, which implies that affected individuals in our study
pedigree have a lower probability to be phenocopies than
affected individuals in the general population, particularly
those with several affected close relatives (the exact probabil-
ities are dependent on the degree of relationship between
patients and the number of intervening affected individuals).
These parameters were chosen to ensure that most of the
linkage information derives from affected individuals. The
rationale for selecting these parameters and results of analyses
that demonstrate the conservatism of this model have been
reported elsewhere (24). Due to the uncertainties regarding
the parameters of genetic transmission, we did not perform
multipoint linkage analysis (31).
Coverage.To assess coverage for a marker, we calculated the
number of informativemeioses at the estimated recombination
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fraction, using the estimate of the variance (the inverse of the
information matrix) (32). Alternatively, when the estimated
frequency of recombination was close to 0 or 1, we applied
Edwards’ equation to calculate the equivalent number of
observations (33). These meioses represent the amount of
linkage information provided by the marker, given the pedi-
gree structure and the genetic model applied. We then as-
sumed linkage to the marker in question and calculated the lod
score that would be observed as a disease gene is hypothetically
moved in increments away from that marker. All regions
around a marker that would have generated a lod score that
exceeded our predesignated thresholds for possible linkage
(0.8 in CR001, 1.2 in CR004, and 1.6 in the combined data)
were considered covered. These lod score thresholds were
derived from simulation analyses showing the expected distri-
bution of lod scores under linkage and nonlinkage (24), and
they approximately represent a result that is 250 times more
likely to occur in linked simulations than in unlinked simula-
tions. We constructed coverage maps (Fig. 1) by superimpos-
ing the regions covered by each marker on the genetic map of
each chromosome. At the end of the stage II screening we had
typed a total of 473 microsatellite markers, with genome
coverage (in the combined data set) of over 94%. Possible
coverage gaps are indicated by unshaded areas and are mainly
concentrated near telomeres. Because the coverage calcula-
tions make use of marker informativeness within the pedi-
grees, the coverage approach thus permits us to detect in-
stances where markers with expected high heterozygosities are
uninformative in our data set.
RESULTS
Linkage Analysis. Of the 473 microsatellites analyzed with
two-point linkage tests, 23 markers exceeded the predesig-
nated thresholds designated for the coverage calculations (in
either CR001 or CR004, or in the combined data set). The
location of these markers, the peak lod scores obtained in each
family and in the combined data set, and the maximum
likelihood estimate of the recombination fraction (u) at which
these lod scores were observed are indicated in Table 1. The
approximate chromosomal locations of these markers are also
depicted in Fig. 1. The distribution of lod scores (for the
maximum likelihood estimate of u in the combined data set)
across the genome is displayed by chromosome in Fig. 2.
The region most suggestive of linkage to BP-I is 18q22–q23,
where five markers exceeded the lod score thresholds in
pedigree CR004, including three of the six markers (over the
whole genome) that exceeded the threshold for the combined
data set. (Detailed investigation of this region is described in
ref. 34). The next most promising region is 11p13–p14, where
lod scores at two contiguous markers equaled or exceeded the
threshold for the combined data sets and a third adjacent
marker exceeded the threshold in family CR001. The threshold
for the combined data set was also equaled for a single marker
near the telomere of 16q (D16S486). The threshold was
exceeded for pedigree CR001 in two adjacent markers near the
18p telomere, but CR004 displayed no suggestion of linkage in
this region. Finally, two of the highest lod scores were observed
in CR004 at markers D3S1285 (2.59) and D7S510 (2.04), both
peaks occurring at u 5 0; however, lod scores for markers that
flank these two loci were positive but did not exceed any of the
predesignated thresholds.
The cluster of suggestive lod scores in 18q22–q23 is adjacent
to, but does not appear to overlap with, a possible localization
to 18q21 for BP (BP-I and BP-II together) recently reported
in a large set of small American families (35). Otherwise, the
promising regions that we identified are not near possible
localizations for broadly defined BP that have been proposed
on chromosomes 11p15 (7), 21q22 (36), Xq28 (8), and in the
pericentromeric region of 18 (37) or for BP-I in Xq24–q27
(38).
DISCUSSION
The genome screening study presented in this paper represents
the first stage of our effort to identify all genes that play a
Table 1. Lod scores for markers exceeding the predesignated coverage thresholds
Marker
name
Distance from
pter, cM
Family CR001 Family CR004 Combined
Zmax
$ 0.8 u
Zmax
$ 1.2 u
Zmed
$ 1.6 u
D1S456 224.6 1.32 0.0 0.0 0.50 0.0 0.50
D2S130 230.1 0.89 0.0 0.12 0.35 0.36 0.26
D3S1285 91.0 0.00 0.50 2.59 0.00 1.15 0.16
D4S171 207.9 1.07 0.07 0.01 0.05 0.22 0.29
D5S427 69.6 1.39 0.0 0.0 0.50 0.7 0.18
D7S510 60.5 0.04 0.40 2.04 0.0 0.82 0.17
D11S929 36.3 0.80 0.11 0.03 0.42 0.43 0.24
D11S1392 38.6 0.86 0.07 0.90 0.23 1.58 0.19
D11S1312 42.0 0.47 0.13 1.77 0.0 1.95 0.05
D13S175 7.4 0.83 0.0 0.0 0.50 0.24 0.15
D15S126 45.5 1.09 0.0 0.0 0.48 0.06 0.40
D16S521 4.6 1.46 0.0 0.41 0.26 1.18 0.17
D16S515 94.8 0.93 0.09 0.01 0.46 0.39 0.25
D16S486 133.6 0.27 0.19 1.29 0.20 1.60 0.20
D17S849 0.60 0.0 0.50 1.22 0.07 0.32 0.14
D18S59 1.1 1.43 0.0 0.0 0.50 0.02 0.46
D18S1105 2.8 0.97 0.0 0.01 0.47 0.01 0.46
D18S71 43.8 0.96 0.0 0.0 0.50 0.0 0.50
D18S64 84.0 0.33 0.11 1.34 0.15 1.67 0.13
D18S55 95.5 0.0 0.50 2.09 0.13 1.51 0.18
D18S61 103.8 0.0 0.50 2.26 0.12 1.94 0.16
D18S488 105.6 0.0 0.50 1.26 0.14 1.02 0.19
D18S1161 113.0 0.0 0.50 1.79 0.16 1.76 0.17
Markers for which lod scores exceeded the predesignated thresholds used for genome coverage calculations are in boldface
type. Zmax is the maximum likelihood estimate of the lod score at the corresponding value of the recombination fraction (u).
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major role in determining susceptibility to BP-I in the genet-
ically homogeneous population of the Central Valley of Costa
Rica. Our aim in this study was to detect those regions that
merit further investigation, rather than to declare unequivocal
linkage to a particular marker or markers. We used a conser-
vative approach to linkage analysis in that almost all of the
information for linkage is derived from individuals with a
severe, narrowly defined phenotype. While this approach
made it very unlikely that we would obtain lod scores greater
than conventional thresholds of statistical significance (e.g., $
3), it increased our confidence in the robustness of the most
suggestive findings.
Our goal of identifying all suggestive regions and weighing
the relative importance of findings required complete screen-
ing of the genome. We developed the coverage approach to
gauge the progress of this effort. Conventionally, the thor-
oughness of genome screening is evaluated by excluding
genome regions from linkage under given genetic models. This
approach, which is highly sensitive to misspecification of
genetic models, may be poorly suited for genome screening
studies of complex traits; it is tied to the expectation of finding
linkage at a single locus and demonstrating absence of linkage
at all other locations in the genome. Additionally, exclusion
analyses do not differentiate between genome regions where
linkage is not excluded because markers are uninformative in
the study population from those in which the genotype data are
simply ambiguous. In contrast, the coverage approach is
designed for studies aimed at genome screening rather than for
studies whose goal is to demonstrate a single unequivocal
linkage finding, and it provides explicit data regarding the
informativeness of markers in the study pedigrees. Its use
lessens the possibility that one would prematurely dismiss a
given genome region as being unpromising for further study.
Because the exact genetic length of chromosomes is not
clearly established, it is impossible to be certain that one has
screened the entire genome. Although we report that we have
covered about 94% of the genome (under the 90% dominant
model) at the thresholds described above, we believe that this
probably represents an underestimate. The remaining cover-
age gaps in our study occur predominantly at or near telo-
meres; as we used the upper-bound estimates for the length of
each chromosome, it is likely that the actual coverage gaps in
these regions are smaller than our conservative assessment.
Coverage results are model dependent and, given the un-
certainty regarding the true model of genetic transmission of
BP-I, it is possible that other potential localizations would
emerge under different models. We therefore plan to reana-
lyze our data under a range of single-locus models (24).
In weighing the relative importance of our findings, we
considered the presence of consistently positive lod scores over
FIG. 1. Extent of marker coverage of each chromosome. Coverage is defined as regions for which a lod score of at least 1.6 would have been
detected (in the combined data set) for markers truly linked to BP-I under the model that we employed. Areas that remain uncovered (at this
threshold) are unshaded. Markers for which lod scores were obtained that exceeded the predesignated coverage thresholds in CR001, CR004, or
the combined data set are shown at their approximate chromosomal position. The symbols to the right of the chromosome indicate the thresholds
exceeded at that marker: l signifies that the lod score at a marker exceeded the threshold of 0.8 in CR001; l signifies that the lod score exceeded
the threshold of 1.2 in CR004; and w signifies that the lod score exceeded the threshold of 1.6 in the combined data set.
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a given region to be of greater significance than isolated peak
lod scores. Such clustering suggests true cosegregation of
markers and phenotypes (i.e., alleles are shared identical by
descent rather than identical by state) and is more readily
observed in analyses of a few large pedigrees (as in our study)
than in examinations of several smaller families. The most
striking clustering of suggestive results is found in 18q22–q23.
The localization of a BP-I gene in this region is supported by
more extensive studies, as discussed in a previous paper (34).
Other regions that merit further investigation on the basis of
clustering of positive lod scores include 11p13–p14 and the
telomere of 18p. Although we recognize that isolated occur-
rences of suggestive lod scores are likely to represent spurious
results, the magnitudes of the lod scores obtained in CR004 at
markers D3S1285 and D7S510 render these regions worthy of
further examination.
In conclusion, through genome screening (the first stage of
a multistep process for identifying genes for complex traits), we
have identified regions that warrant further study in the search
for BP-I genes. The second and third steps in this process
consist of delineating clear candidate regions and fine mapping
studies. The genetic homogeneity of the Costa Rican popula-
tion should facilitate our completion of these steps; it should
be feasible to collect and genotype an additional independent
FIG. 2. The lod scores for the maximum likelihood estimates (MLEs) of u in the combined sample for the 473 microsatellite markers typed
in the genome screen. The MLEs of u are represented by different colors: red, u , 0.10; green, 0.10 # u , 0.40; blue, u $ 0.40. Note that the scale
for the x-axis (distance from pter in cM) changes with chromosomes. Marker names and actual MLEs of u are available from N.B.F. by request.
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sample of BP-I patients from the Costa Rican Central Valley
to conduct haplotype and LD analyses. It is thus practical to
positionally clone one or more genes that play a role in BP-I
susceptibility in this population.
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